MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41393-019-0251-y

Медицинская библиотека · Spinal cord · 2019

Probiotics [LGG-BB12 or RC14-GR1] versus placebo as prophylaxis for urinary tract infection in persons with spinal cord injury [ProSCIUTTU]: a randomised controlled trial.

Toh Swee-Ling, Lee Bonsan Bonne, Ryan Suzanne, Simpson Judy M, Clezy Kate, Bossa Laetitia, Rice Scott Alan, Marial Obaydullah, Weber Gerard Hogan, Kaur Jasbeer, Boswell-Ruys Claire Louise, Goodall Stephen, Middleton James Walter, Tuderhope Mark, Kotsiou George

СтатьяМногоцентровое исследованиеРандомизированное исследованиеПеревод в очереди

Аннотация

STUDY

DESIGN

Randomised double-blind factorial-design placebo-controlled trial.

OBJECTIVE

Urinary tract infections (UTIs) are common in people with spinal cord injury (SCI). UTIs are increasingly difficult to treat due to emergence of multi-resistant organisms. Probiotics are efficacious in preventing UTIs in post-menopausal women. We aimed to determine whether probiotic therapy with Lactobacillus reuteri RC-14+Lactobacillus GR-1 (RC14-GR1) and/or Lactobacillus rhamnosus GG+Bifidobacterium BB-12 (LGG-BB12) are effective in preventing UTI in people with SCI.

SETTING

Spinal units in New South Wales, Australia with their rural affiliations.

METHODS

We recruited 207 eligible participants with SCI and stable neurogenic bladder management. They were randomised to one of four arms: RC14-GR1+LGG-BB12, RC14-GR1+placebo, LGG-BB12+ placebo or double placebos for 6 months. Randomisation was stratified by bladder management type and inpatient or outpatient status. The primary outcome was time to occurrence of symptomatic UTI.

RESULTS

Analysis was based on intention to treat. Participants randomised to RC14-GR1 had a similar risk of UTI as those not on RC14-GR1 (HR 0.67; 95% CI: 0.39-1.18; P = 0.17) after allowing for pre-specified covariates. Participants randomised to LGG-BB12 also had a similar risk of UTI as those not on LGG-BB12 (HR 1.29; 95% CI: 0.74-2.25; P = 0.37). Multivariable post hoc survival analysis for RC14-GR1 only vs. the other three groups showed a potential protective effect (HR 0.46; 95% CI: 0.21-0.99; P = 0.03), but this result would need to be confirmed before clinical application.

CONCLUSION

In this RCT, there was no effect of RC14-GR1 or LGG-BB12 in preventing UTI in people with SCI.

Для цитирования: Toh Swee-Ling, Lee Bonsan Bonne, Ryan Suzanne, Simpson Judy M, Clezy Kate, Bossa Laetitia, Rice Scott Alan, Marial Obaydullah, Weber Gerard Hogan, Kaur Jasbeer, Boswell-Ruys Claire Louise, Goodall Stephen, Middleton James Walter, Tuderhope Mark, Kotsiou George. Probiotics [LGG-BB12 or RC14-GR1] versus placebo as prophylaxis for urinary tract infection in persons with spinal cord injury [ProSCIUTTU]: a randomised controlled trial.. Spinal cord. 2019. DOI: 10.1038/s41393-019-0251-y.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.